In conclusion, these findings point to Pz-1 as a promising anti-cancer agent towards either RET or TRKA driven cancers, though, in a clinical setting its VEGFR2 activity that probably collaborates with RET and TRKA activity, has to be kept under check because it may be responsible of dose-limiting toxicity. This evidence concerns the gene RET and cancer.